{"organizations": [], "uuid": "4d84ed407e3c7edf26218be72027793c839f947d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-announces-us/brief-aerie-pharmaceuticals-announces-u-s-launch-of-rhopressa-0-02-idUSFWN1S70P0", "country": "US", "domain_rank": 408, "title": "BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T13:45:00.000+03:00", "replies_count": 0, "uuid": "4d84ed407e3c7edf26218be72027793c839f947d"}, "author": "", "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-announces-us/brief-aerie-pharmaceuticals-announces-u-s-launch-of-rhopressa-0-02-idUSFWN1S70P0", "ord_in_thread": 0, "title": "BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-aerie pharmaceuticals announces u.s. launch of rhopr", "sentiment": "negative"}, {"name": "brief-aerie pharmaceuticals announces u.s. launch of rhopressa", "sentiment": "negative"}, {"name": "aerie pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 10:45 AM / in 13 minutes BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02% Reuters Staff\nApril 30 (Reuters) - Aerie Pharmaceuticals Inc:\n* AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSAÂ® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%\n* AERIE - FORMULARY CONTRACTS FOR COMMERCIAL INSURANCE COVERAGE IN 2018, MEDICARE PART D PROGRAM COVERAGE BEGINNING 2019 IN FINAL STAGES OF EXECUTION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-30T13:45:00.000+03:00", "crawled": "2018-04-30T14:07:22.178+03:00", "highlightTitle": ""}